IUPAC name
5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
SMILES
CN(C)N=NC1=C(N=CN1)C(N)=O
Compound class
Antineoplastic Agents; Immunosuppressive Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong);
Therapeutic area
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
Common name
Dacarbazine
IUPAC name
5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
SMILES
CN(C)N=NC1=C(N=CN1)C(N)=O
INCHI
InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)
FORMULA
C6H10N6O
Common name
Dacarbazine
IUPAC name
5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
Molecular weight
182.183
clogP
-0.092
clogS
-0.881
HBond Acceptor
5
HBond Donor
3
Total Polar Surface Area
99.73
Number of Rings
1
Rotatable Bond
3
